Susquehanna International Group, LLP Ultragenyx Pharmaceutical Inc. Call Options Transaction History

Susquehanna International Group, LLP

$527 Billion
Q2 2024

Call Options

28 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 15, 2024	BUY	$37.42 - $51.61 $1.26 Million - $1.73 Million	33,600 Added 25.47%	165,500 $6.8 Million
Q1 2024 May 07, 2024	BUY	$43.02 - $53.69 $877,608 - $1.1 Million	20,400 Added 18.3%	131,900 $6.16 Million
Q4 2023 Feb 14, 2024	SELL	$31.73 - $49.19 $3.87 Million - $6 Million	-121,900 Reduced 52.23%	111,500 $5.33 Million
Q3 2023 Nov 14, 2023	BUY	$34.92 - $46.66 $4.81 Million - $6.43 Million	137,700 Added 143.89%	233,400 $8.32 Million
Q2 2023 Aug 11, 2023	BUY	$37.35 - $52.15 $683,505 - $954,345	18,300 Added 23.64%	95,700 $4.41 Million
Q1 2023 May 16, 2023	SELL	$36.99 - $48.71 $2.02 Million - $2.65 Million	-54,500 Reduced 41.32%	77,400 $3.1 Million
Q4 2022 Feb 14, 2023	BUY	$33.72 - $46.33 $1.3 Million - $1.78 Million	38,500 Added 41.22%	131,900 $6.11 Million
Q3 2022 Nov 14, 2022	BUY	$39.96 - $66.14 $2.87 Million - $4.74 Million	71,700 Added 330.41%	93,400 $3.87 Million
Q2 2022 Aug 15, 2022	BUY	$45.8 - $85.4 $778,600 - $1.45 Million	17,000 Added 361.7%	21,700 $1.3 Million
Q1 2022 May 16, 2022	BUY	$62.2 - $84.4 $143,060 - $194,120	2,300 Added 95.83%	4,700 $341,000
Q4 2021 Feb 14, 2022	SELL	$73.71 - $87.86 $663,390 - $790,740	-9,000 Reduced 78.95%	2,400 $202,000
Q3 2021 Nov 15, 2021	SELL	$77.92 - $102.4 $1.65 Million - $2.17 Million	-21,200 Reduced 65.03%	11,400 $1.03 Million
Q2 2021 Aug 11, 2021	SELL	$92.19 - $115.71 $4.94 Million - $6.2 Million	-53,600 Reduced 62.18%	32,600 $3.11 Million
Q1 2021 May 17, 2021	SELL	$106.9 - $167.73 $6.35 Million - $9.96 Million	-59,400 Reduced 40.8%	86,200 $9.82 Million
Q4 2020 Feb 16, 2021	BUY	$84.4 - $177.39 $11.1 Million - $23.3 Million	131,200 Added 911.11%	145,600 $20.2 Million
Q3 2020 Nov 16, 2020	SELL	$72.98 - $90.0 $3.69 Million - $4.55 Million	-50,500 Reduced 77.81%	14,400 $1.18 Million
Q2 2020 Aug 14, 2020	BUY	$46.91 - $78.22 $595,757 - $993,394	12,700 Added 24.33%	64,900 $5.08 Million
Q1 2020 May 15, 2020	BUY	$33.8 - $62.9 $1.56 Million - $2.9 Million	46,100 Added 755.74%	52,200 $2.32 Million
Q4 2019 Feb 14, 2020	BUY	$36.08 - $45.83 $3,608 - $4,583	100 Added 1.67%	6,100 $261,000
Q3 2019 Nov 14, 2019	SELL	$42.5 - $63.11 $5.24 Million - $7.78 Million	-123,200 Reduced 95.36%	6,000 $257,000
Q2 2019 Aug 14, 2019	BUY	$54.93 - $74.36 $362,538 - $490,776	6,600 Added 5.38%	129,200 $8.2 Million
Q1 2019 May 15, 2019	BUY	$39.87 - $69.36 $3.78 Million - $6.58 Million	94,900 Added 342.6%	122,600 $8.5 Million
Q4 2018 Feb 14, 2019	SELL	$38.89 - $77.3 $4.67 Million - $9.28 Million	-120,000 Reduced 81.25%	27,700 $1.2 Million
Q3 2018 Nov 14, 2018	BUY	$71.81 - $90.15 $2.66 Million - $3.34 Million	37,100 Added 33.54%	147,700 $11.3 Million
Q2 2018 Aug 14, 2018	BUY	$48.54 - $85.31 $4.43 Million - $7.79 Million	91,300 Added 473.06%	110,600 $8.5 Million
Q1 2018 May 15, 2018	SELL	$44.33 - $58.52 $638,352 - $842,688	-14,400 Reduced 42.73%	19,300 $984,000
Q4 2017 Feb 14, 2018	SELL	$43.54 - $57.32 $2.05 Million - $2.7 Million	-47,100 Reduced 58.29%	33,700 $1.56 Million
Q3 2017 Nov 14, 2017	BUY	$49.79 - $66.32 $4.02 Million - $5.36 Million	80,800	80,800 $4.3 Million

Others Institutions Holding RARE

# of Institutions

287

Shares Held

88.1M

Call Options Held

505K

Put Options Held

198K

Vanguard Group Inc Valley Forge, PA

9.78M
Shares

$532 Million
0.01% of portfolio
Black Rock Inc. New York, NY

5.6M
Shares

$305 Million
0.01% of portfolio
Sands Capital Management, LLC Arlington, VA

5.35M
Shares

$291 Million
0.68% of portfolio
Wellington Management Group LLP Boston, MA

4.56M
Shares

$248 Million
0.03% of portfolio
Rtw Investments, LP New York, NY

3.26M
Shares

$177 Million
2.24% of portfolio

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.81B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account